BEONE MEDICINES LTD.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.34B | $3.81B | $2.46B | $1.42B | $1.18B | $308.9M | $428.2M | $198.2M |
| Cost of Revenue | — | — | — | $286.5M | $164.9M | $70.7M | $71.2M | $28.7M |
| Gross Profit | $4.67B | $3.22B | $2.08B | $1.13B | $1.01B | $238.2M | $357.0M | $169.5M |
| Gross Margin | 87.5% | 84.4% | 84.5% | 79.8% | 86.0% | 77.1% | 83.4% | 85.5% |
| Operating Expenses | ||||||||
| Research & Development | $2.15B | $1.95B | $1.78B | $1.64B | $1.46B | $1.29B | $927.3M | $679.0M |
| SG&A Expense | $2.08B | $1.83B | $1.51B | $1.28B | $990.1M | $600.2M | $388.2M | $195.4M |
| Operating Income | $447.1M | $-568.2M | $-1.21B | $-1.79B | $-1.44B | $-1.66B | $-959.9M | $-705.8M |
| Operating Margin | 8.4% | -14.9% | -49.1% | -126.4% | -122.3% | -536.7% | -224.2% | -356.1% |
| Interest Expense | $50.0M | $46.9M | $20.8M | $21.7M | $29.3M | $18.3M | $15.2M | $13.1M |
| Pretax Income | $416.9M | $-533.0M | $-825.8M | $-1.96B | $-1.44B | $-1.62B | $-943.6M | $-689.8M |
| Income Tax Expense | $129.9M | $111.8M | $55.9M | $42.8M | $19.2M | $10.4M | $7.0M | $-15.8M |
| Net Income | $286.9M | $-644.8M | $-881.7M | $-2.00B | $-1.46B | $-1.62B | $-948.6M | $-673.8M |
| Net Margin | 5.4% | -16.9% | -35.9% | -141.5% | -123.9% | -526.1% | -221.5% | -339.9% |
| EPS (Basic) | $0.20 | $-0.47 | $-0.65 | $-1.49 | $-1.21 | $-1.50 | $-1.22 | $-0.93 |
| EPS (Diluted) | $0.19 | $-0.47 | $-0.65 | $-1.49 | $-1.21 | $-1.50 | $-1.22 | $-0.93 |
| Shares Outstanding (Basic) | 1.42B | 1.37B | 1.36B | 1.34B | 1.21B | 1.09B | 780.7M | 776.3M |
| Shares Outstanding (Diluted) | 1.47B | 1.37B | 1.36B | 1.34B | 1.21B | 1.09B | 780.7M | 776.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |